Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24910485 | 0.70 | TSHR (0.46) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19928536 | 0.70 | KDM4E (0.32) | CYP1A2 | |
| SCHEMBL27115531 | 0.68 | KDM4E (0.31) | CYP1A2 | |
| SCHEMBL21074376 | 0.67 | GPR3 (0.35) | TSHRCYP1A2 | |
| SCHEMBL7519328 | 0.67 | TSHR (1.00) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12169409 | 0.63 | TSHR (0.58) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17171671 | 0.62 | TSHR (0.77) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24000930 | 0.62 | MAPK1 (0.39) | TSHR | |
| SCHEMBL9354769 | 0.61 | ALOX15 (0.68) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14327701 | 0.61 | KDM4E (0.32) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HCCS | TSHR 4408/4885PTGS2 2500/4885PTGS1 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.